
Tempus AI Inc (NASDAQ:TEM) stock is trading lower on Monday as the stock is pulling back from an approximately 20% surge over the last week.
The recent surge in the stock was driven by momentum from Phase 3 INTerpath-001 results from Merck & Co. Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA) of intismeran autogene (a custom mRNA neoantigen therapy) paired with Keytruda for advanced melanoma.
The data puts a spotlight on the company’s $1.5 billion Personalis Inc. (NASDAQ:PSNL) deal.
Moderna uses Personalis’ sequencing platform to analyze tumor tissue and identify specific neoantigens needed to manufacture individualized doses.
On Monday, Tempus received FDA 510(k) clearance for ECG-PH, an AI product intended to detect signs of pulmonary hypertension from a standard ECG.
The clearance adds pulmonary hypertension to the company’s FDA-cleared AI products alongside atrial fibrillation and low ejection fraction.
The stock carries a Hold rating with an average price forecast of $61.27. Recent analyst moves include:
Below is the Benzinga Edge scorecard for Tempus AI, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Tempus AI’s Benzinga Edge signal reveals a momentum-driven story, with the scorecard emphasizing trend strength more than fundamentals.
For longer-term traders, that typically means risk management around support/resistance matters more than trying to “average” the move on volatile days.
TEM Stock Price Activity: Tempus AI shares were down 6.78% to $67.76 at the time of publication on Monday, according to Benzinga Pro data.
Photo courtesy: Piotr Swat via Shutterstock